The use of interferon beta and glatiramer acetate in multiple sclerosis

Seminars in Neurology

Volumn 33, Issue 1, 2013, Pages 13-25

  Goodin, Douglas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

glatiramer acetate; interferon beta; multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 7; MESSENGER RNA; PLACEBO; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANXIETY DISORDER; ARTICLE; CLINICAL RESEARCH; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; DYSPNEA; FOLLOW UP; HEART PALPITATION; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; THORAX PAIN; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; TREATMENT OUTCOME;

EID: 84878305066     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0033-1343792     Document Type: Article

References (101)

1. Weinshenker B. G., Bass B., Rice G. PA., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain: 1989; 112 Pt 1 133 146 (Pubitemid 19056478)
2. Weinshenker B. G., Bass B., Rice G. P., et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain: 1989; 112 Pt 6 1419 1428 (Pubitemid 20024212)
3. Weinshenker B. G. Epidemiology of multiple sclerosis. Neurol Clin: 1996; 14 2 291 308 (Pubitemid 26157423)
4. Tremlett H., Paty D., Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology: 2006; 66 2 172 177 (Pubitemid 43970148)
5. th ed. London Churchill Livingston: 2006
6. Conlon P., Oksenberg J. R., Zhang J., Steinman L. The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system. Neurobiol Dis: 1999; 6 3 149 166 (Pubitemid 29297817)
7. Ferguson B., Matyszak M. K., Esiri M. M., Perry V. H. Axonal damage in acute multiple sclerosis lesions. Brain: 1997; 120 Pt 3 393 399 (Pubitemid 27153632)
8. Trapp B. D., Peterson J. P., Ransohoff R. M., Rudick R., Mörk S., Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med: 1998; 338 5 278 285 (Pubitemid 28065253)
9. Bar-Or A., Oliveira E. M., Anderson D. E., Hafler D. A. Molecular pathogenesis of multiple sclerosis. J Neuroimmunol: 1999; 100 1-2 252 259 (Pubitemid 30038258)
10. Lublin F. D., Reingold S. C. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis Defining the clinical course of multiple sclerosis: results of an international survey. Neurology: 1996; 46 4 907 911 (Pubitemid 26134623)
11. Kurtzke J. F. A new scale for evaluating disability in multiple sclerosis. Neurology: 1955; 5 8 580 583
12. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology: 1983; 33 11 1444 1452 (Pubitemid 14237132)
13. Goodin D. S. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol: 2006; 59 4 597 605
14. Goodin D. S., Traboulsee A., Knappertz V., et al. 16-Year Long Term Follow-up Study Investigators Relationship between early clinical characteristics and long term disability outcomes: 16. year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry: 2012; 83 3 282 287
15. Goodin D. S., Jones J., Li D., et al. 16-Year Long-Term Follow-up Study Investigators Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS ONE: 2011; 6 11 e22444
16. Trojano M., Pellegrini F., Fuiani A., et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol: 2007; 61 4 300 306 (Pubitemid 46676729)
17. Renoux C., Suissa S. Immortal time bias in the study of effectiveness of interferon-β in multiple sclerosis. Ann Neurol: 2008; 64 1 109 110, author reply 110
18. Shirani A., Zhao Y., Karim M. E., et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA: 2012; 308 3 247 256
19. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf: 2007; 16 3 241 249 (Pubitemid 46431687)
20. Rosenbaum P. R., Rubin D. B. The central role of the propensity score in observational studies for causal effects. Biometrica: 1983; 70 41 55
21. Trojano M., Pellegrini F. Reply (to Renoux & Suissa). Ann Neurol: 2008; 64 110
22. Goodin D. S., Reder A. T., Cutter G. Treatment with interferon beta for multiple sclerosis. JAMA: 2012; 308 16 1627, author reply 1627-1628
23. Came P. E., Carter W. A., eds. Interferons and Their Applications. Berlin Springer-Verlag: 1984
24. Der S. D., Zhou A., Williams B. RG, Silverman R. H. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc Natl Acad Sci U S A: 1998; 95 26 15623 15628 (Pubitemid 29018750)
25. Reder A. T., ed. Interferon therapy of multiple sclerosis. New York Marcel Dekker, Inc.: 2000
26. Goodbourn S., Didcock L., Randall R. E. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol: 2000; 81 Pt 10 2341 2364
27. de Veer M. J., Holko M., Frevel M., et al. Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol: 2001; 69 6 912 920 (Pubitemid 32577892)
28. Servant M. J., Tenoever B., Lin R. Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J Interferon Cytokine Res: 2002; 22 1 49 58 (Pubitemid 34161282)
29. Kerr I. M., Costa-Pereira A. P., Lillemeier B. F., Strobl B. Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett: 2003; 546 1 1 5 (Pubitemid 36782275)
30. The IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology: 1993; 43 4 655 661
31. Paty D. W., Li D. K. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology: 1993; 43 4 662 667 (Pubitemid 23121952)
32. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology: 1995; 45 7 1277 1285
33. Jacobs L. D., Cookfair D. L., Rudick R. A., et al. The Multiple Sclerosis Collaborative Research Group (MSCRG) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol: 1996; 39 3 285 294 (Pubitemid 26100751)
34. Rudick R. A., Goodkin D. E., Jacobs L. D., et al. The Multiple Sclerosis Collaborative Research Group (MSCRG) Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology: 1997; 49 2 358 363 (Pubitemid 27368867)
35. Simon J. H., Jacobs L. D., Campion M., et al. The Multiple Sclerosis Collaborative Research Group Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann Neurol: 1998; 43 1 79 87 (Pubitemid 28124651)
36. Khatri B. O., McQuillen M. P. Disease modifying therapies in multiple sclerosis. Neurology: 2002; 59 3 472 473, author reply 472-473
37. Biogen Inc. Summary Basis of Approval FDA Official Document for License of Interferon Beta-1a (Avonex). Cambridge, MA Biogen Inc: 1995
38. Rudick R. A., Fisher E., Lee J. C., Simon J., Jacobs L. Multiple Sclerosis Collaborative Research Group Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology: 1999; 53 8 1698 1704 (Pubitemid 29530342)
39. Fischer J. S., Priore R. L., Jacobs L. D., et al. Multiple Sclerosis Collaborative Research Group Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol: 2000; 48 6 885 892
40. Miller D. M., Weinstock-Guttman B., Bourdette D., You X., Foulds P., Rudick R. A. Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon beta-1a. Mult Scler: 2011; 17 6 734 742
41. Bermel R. A., Weinstock-Guttman B., Bourdette D., Foulds P., You X., Rudick R. A. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study. Mult Scler: 2010; 16 5 588 596
42. PRISMS Study Group Randomized double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet: 1998; 352 9139 1498 1504
43. Li D. K., Paty D. W. UBC MS/MRI Analysis Research Group, PRISMS Study Group Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol: 1999; 46 2 197 206 (Pubitemid 29382876)
44. European Study Group on Interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet: 1998; 352 9139 1491 1497
45. Panitch H., Miller A., Paty D., Weinshenker B. North American Study Group on Interferon beta-1b in Secondary Progressive MS Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology: 2004; 63 10 1788 1795 (Pubitemid 39532370)
46. Kappos L., Weinshenker B., Pozzilli C., et al. European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology: 2004; 63 10 1779 1787 (Pubitemid 39532369)
47. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology: 2001; 56 11 1496 1504
48. Li D. K., Zhao G. J., Paty D. W. University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology: 2001; 56 11 1505 1513 (Pubitemid 32532262)
49. Cohen J. A., Cutter G. R., Fischer J. S., et al. IMPACT Investigators Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology: 2002; 59 5 679 687
50. Jacobs L. D., Beck R. W., Simon J. H., et al. CHAMPS Study Group Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med: 2000; 343 13 898 904
51. Comi G., Filippi M., Barkhof F., et al. Early Treatment of Multiple Sclerosis Study Group Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet: 2001; 357 9268 1576 1582 (Pubitemid 32488815)
52. Kappos L., Freedman M. S., Polman C. H., et al. BENEFIT Study Group Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet: 2007; 370 9585 389 397 (Pubitemid 47189673)
53. Kappos L., Traboulsee A., Constantinescu C., et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology: 2006; 67 6 944 953 (Pubitemid 44454583)
54. Goodin D. S., Reder A. T., Ebers G. C., et al. Survival in MS patients 21 years after initiation of the interferon beta-1b pivotal trial. Neurology: 2012; 78 17 1315 1322
55. Goodin D. S., Ebers G. C., Cutter G., et al. Cause of death in MS: Long-term follow-up of a randomized cohort, 21-years after the start of the pivotal IFNB-1b study. BMJ Open: 2012; 2 6. pii: e001972
56. Panitch H., Goodin D. S., Francis G., et al. EVIDENCE Study Group. Evidence of interferon dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology: 2002; 59 10 1496 1506 (Pubitemid 35387053)
57. Durelli L., Verdun E., Barbero P., et al. Independent Comparison of Interferon (INCOMIN) Trial Study Group Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet: 2002; 359 9316 1453 1460 (Pubitemid 34457761)
58. O'Connor P., Filippi M., Arnason B., et al. BEYOND Study Group 250 microg or 500 microg interferon beta-1b versus 20. mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol: 2009; 8 10 889 897
59. Deisenhammer F., Mayringer I., Harvey J., et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology: 2000; 54 11 2055 2060 (Pubitemid 30397201)
60. Stürzebecher S., Maibauer R., Heuner A., Beckmann K., Aufdembrinke B. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res: 1999; 19 11 1257 1264
61. Salmon P., Le Cotonnec J. Y., Galazka A., Abdul-Ahad A., Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res: 1996; 16 10 759 764 (Pubitemid 26389112)
62. Munafo A., Trinchard-Lugan I., Nguyen T. XQ, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol: 1998; 5 1 7
63. Goodin D. S., Frohman E. M., Hurwitz B., et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2007; 68 13 977 984 (Pubitemid 46569129)
64. Goodin D. S., Hurwitz B., Noronha A. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res: 2007; 35 2 173 187 (Pubitemid 46831066)
65. Goodin D. S. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (Correspondence). J Int Med Res: 2008; 36 208 210
66. Farrell R., Bendtzen K., Bertolotto A., et al. European NABINMS Consortium Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res: 2008; 36 1 204 208, author reply 208-210
67. Pachner A. R. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2007; 69 1555 1556, author reply 1565
68. Polman C. H., Deisenhammer F., Giovannoni G., Killestein J., Schellekens H. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2007; 69 15 1553 1555, author reply 1555
69. Sorensen P. S., Bertolotto A. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology: 2007; 69 15 1552 1553, author reply 1553 (Pubitemid 47537865)
70. Pachner A. R., Warth J. D., Pace A., Goelz S. INSIGHT investigators Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology: 2009; 73 18 1493 1500
71. Pachner A. R., Dail D., Pak E., Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol: 2005; 166 1-2 180 188 (Pubitemid 41078773)
72. Pachner A. R., Narayan K., Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology: 2006; 66 3 444 446 (Pubitemid 43739958)
73. Hesse D., Sellebjerg F., Sorensen P. S. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology: 2009; 73 5 372 377
74. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc, B: 1995; 57 289 300
75. Hartung H. P., Freedman M. S., Polman C. H., et al. BENEFIT Study Group Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology: 2011; 77 9 835 843
76. Goodin D. S., Hartung H. P., O'Connor P., et al. BEYOND Study Group Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler: 2012; 18 2 181 195
77. Sorensen P. S., Koch-Henriksen N., Ross C., Clemmesen K. M., Bendtzen K. Danish Multiple Sclerosis Study Group Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology: 2005; 65 1 33 39 (Pubitemid 40967773)
78. Petkau A. J., White R. A., Ebers G. C., et al. IFNB Multiple Sclerosis Study Group Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler: 2004; 10 2 126 138 (Pubitemid 38499903)
79. Rice G. P., Paszner B., Oger J., Lesaux J., Paty D., Ebers G. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology: 1999; 52 6 1277 1279 (Pubitemid 29177937)
80. Bellomi F., Scagnolari C., Tomassini V., et al. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci: 2003; 215 1-2 3 8 (Pubitemid 37272189)
81. Reder A. T., Ebers G. C., Traboulsee A., et al. Investigators of the 16-Year Long-Term Follow-Up Study Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology: 2010; 74 23 1877 1885
82. Teitelbaum D., Aharoni R., Sela M., Arnon R. Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci U S A: 1991; 88 21 9528 9532 (Pubitemid 21915664)
83. Teitelbaum D., Milo R., Arnon R., Sela M. Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci U S A: 1992; 89 1 137 141
84. Lando Z., Teitelbaum D., Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol: 1979; 123 5 2156 2160 (Pubitemid 10242461)
85. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol: 1971; 1 4 242 248
86. Bornstein M. B., Miller A., Slagle S., et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med: 1987; 317 7 408 414 (Pubitemid 17131177)
87. Johnson K. P., Brooks B. R., Cohen J. A., et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology: 1995; 45 7 1268 1276
88. Johnson K. P., Brooks B. R., Cohen J. A., et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology: 1998; 50 3 701 708
89. Comi G., Filippi M., Wolinsky J. S. European/Canadian Glatiramer Acetate Study Group European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol: 2001; 49 3 290 297 (Pubitemid 32202781)
90. Mikol D. D., Barkhof F., Chang P., et al. REGARD study group Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol: 2008; 7 10 903 914
91. Bornstein M. B., Miller A., Slagle S., et al. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology: 1991; 41 4 533 539
92. Wolinsky J. S., Narayana P. A., O'Connor P., et al. PROMiSe Trial Study Group Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol: 2007; 61 1 14 24 (Pubitemid 46214240)
93. Comi G., Martinelli V., Rodegher M., et al. PreCISe study group Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet: 2009; 374 9700 1503 1511
94. Johnson K. P., Brooks B. R., Ford C. C., et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler: 2000; 6 4 255 266
95. Ford C. C., Johnson K. P., Lisak R. P., Panitch H. S., Shifronis G., Wolinsky J. S. Copaxone Study Group A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler: 2006; 12 3 309 320 (Pubitemid 43827186)
96. Ford C., Goodman A. D., Johnson K., et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler: 2010; 16 3 342 350
97. Goodin D. S. Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors. J Neurol: 2004; 251 05 v3 v11
98. Edgar C. M., Brunet D. G., Fenton P., McBride E. V., Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci: 2004; 31 1 58 63 (Pubitemid 38325760)
99. Polman C. H., O'Connor P. W., Havrdova E., et al. AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med: 2006; 354 9 899 910
100. Kappos L., Radue E. W., O'Connor P., et al. FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med: 2010; 362 5 387 401
101. O'Connor P., Wolinsky J. S., Confavreux C., et al. TEMSO Trial Group Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med: 2011; 365 14 1293 1303